vs
Side-by-side financial comparison of Borealis Foods Inc. (BRLS) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Borealis Foods Inc. is the larger business by last-quarter revenue ($7.1M vs $5.5M, roughly 1.3× Taysha Gene Therapies, Inc.). Borealis Foods Inc. runs the higher net margin — -53.2% vs -507.8%, a 454.5% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -12.0%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -2.4%).
Borealis Foods Inc is a food technology enterprise specializing in developing and producing high-quality plant-based protein products including plant-based meat alternatives. It mainly serves retail and food service customers across North America and Europe, focusing on delivering affordable, nutritious sustainable food options matching the taste of conventional animal-derived meat.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
BRLS vs TSHA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.1M | $5.5M |
| Net Profit | $-3.8M | $-27.9M |
| Gross Margin | 14.6% | — |
| Operating Margin | -27.1% | -516.0% |
| Net Margin | -53.2% | -507.8% |
| Revenue YoY | -12.0% | 171.3% |
| Net Profit YoY | 21.8% | -48.3% |
| EPS (diluted) | $-0.18 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.5M | ||
| Q3 25 | $7.1M | $0 | ||
| Q2 25 | $7.2M | $2.0M | ||
| Q1 25 | $6.8M | $2.3M | ||
| Q4 24 | $6.8M | $2.0M | ||
| Q3 24 | $8.1M | $1.8M | ||
| Q2 24 | $5.5M | $1.1M | ||
| Q1 24 | $7.9M | $3.4M |
| Q4 25 | — | $-27.9M | ||
| Q3 25 | $-3.8M | $-32.7M | ||
| Q2 25 | $-4.6M | $-26.9M | ||
| Q1 25 | $-4.2M | $-21.5M | ||
| Q4 24 | $-5.8M | $-18.8M | ||
| Q3 24 | $-4.8M | $-25.5M | ||
| Q2 24 | $-6.3M | $-20.9M | ||
| Q1 24 | $-8.4M | $-24.1M |
| Q4 25 | — | — | ||
| Q3 25 | 14.6% | — | ||
| Q2 25 | 7.2% | — | ||
| Q1 25 | 13.1% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 15.8% | — | ||
| Q2 24 | 7.7% | — | ||
| Q1 24 | 3.1% | — |
| Q4 25 | — | -516.0% | ||
| Q3 25 | -27.1% | — | ||
| Q2 25 | -46.7% | -1347.1% | ||
| Q1 25 | -42.6% | -930.5% | ||
| Q4 24 | -68.4% | -985.8% | ||
| Q3 24 | -44.8% | -1448.4% | ||
| Q2 24 | -94.8% | -1915.4% | ||
| Q1 24 | -88.3% | -713.3% |
| Q4 25 | — | -507.8% | ||
| Q3 25 | -53.2% | — | ||
| Q2 25 | -64.0% | -1353.6% | ||
| Q1 25 | -61.2% | -935.2% | ||
| Q4 24 | -85.3% | -929.0% | ||
| Q3 24 | -59.8% | -1427.5% | ||
| Q2 24 | -115.0% | -1882.0% | ||
| Q1 24 | -106.8% | -705.4% |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.18 | $-0.09 | ||
| Q2 25 | $0.21 | $-0.09 | ||
| Q1 25 | $-0.20 | $-0.08 | ||
| Q4 24 | $-0.82 | $-0.07 | ||
| Q3 24 | $-0.23 | $-0.10 | ||
| Q2 24 | $0.29 | $-0.09 | ||
| Q1 24 | $-0.49 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-12.9M | $246.9M |
| Total Assets | $56.3M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $319.8M | ||
| Q3 25 | — | $297.3M | ||
| Q2 25 | — | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | — | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | — | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | — | $246.9M | ||
| Q3 25 | $-12.9M | $219.0M | ||
| Q2 25 | $-9.2M | $248.7M | ||
| Q1 25 | $-4.8M | $55.1M | ||
| Q4 24 | $-695.9K | $71.5M | ||
| Q3 24 | $5.1M | $88.8M | ||
| Q2 24 | $9.9M | $108.9M | ||
| Q1 24 | $16.2M | $53.8M |
| Q4 25 | — | $343.3M | ||
| Q3 25 | $56.3M | $316.6M | ||
| Q2 25 | $57.3M | $333.3M | ||
| Q1 25 | $58.4M | $138.4M | ||
| Q4 24 | $60.0M | $160.4M | ||
| Q3 24 | $61.9M | $180.2M | ||
| Q2 24 | $63.6M | $200.4M | ||
| Q1 24 | $70.3M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-190.6K | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.7M | ||
| Q3 25 | $-190.6K | $-24.2M | ||
| Q2 25 | $-2.2M | $-20.2M | ||
| Q1 25 | $-1.4M | $-22.0M | ||
| Q4 24 | $-819.4K | $-18.3M | ||
| Q3 24 | $-3.3M | $-21.6M | ||
| Q2 24 | $-4.2M | $-21.5M | ||
| Q1 24 | $-6.8M | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | $-1.4M | — | ||
| Q4 24 | $-951.6K | $-18.3M | ||
| Q3 24 | $-3.7M | $-21.6M | ||
| Q2 24 | $-4.7M | $-21.7M | ||
| Q1 24 | $-7.3M | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -20.3% | — | ||
| Q4 24 | -14.1% | -905.5% | ||
| Q3 24 | -46.1% | -1210.9% | ||
| Q2 24 | -86.7% | -1951.9% | ||
| Q1 24 | -92.7% | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 2.0% | 0.1% | ||
| Q3 24 | 5.6% | 2.0% | ||
| Q2 24 | 9.4% | 18.1% | ||
| Q1 24 | 7.0% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
